R Khan
What are the participants’ perspectives of taking melatonin for the treatment of nocturia in Multiple Sclerosis? -a qualitative study embedded within a double blind RCT
Khan, R; Uren, A; Canham, L; Cottrell, D; Drake, MJ; Cotterill, N
Authors
A Uren
L Canham
D Cottrell
MJ Drake
N Nikki Cotterill Nikki.Cotterill@uwe.ac.uk
Professor of Long Term Conditions (Continence Care)
Abstract
Background: Multiple Sclerosis (MS) is a chronic neurological disorder caused by neurodegeneration within the central nervous system. It results in impaired physical, cognitive and psychological functioning and can also lead to lower urinary tract symptoms including nocturia. While clinical trials have suggested an association between nocturia and melatonin secretion, to our knowledge, no qualitative research has been conducted on the experience of taking melatonin to treat nocturia in progressive MS within a clinical trial.
Methods: 17 semi-structured qualitative interviews were conducted as part of a double-blind, randomised, placebo controlled, crossover, clinical trial with consenting adults with MS. Interviews explored participants’ experiences of nocturia associated with MS and their experience of taking melatonin as a trial treatment for nocturia versus a placebo. Data was analysed using a thematic analysis.
Results: Themes on the experience of nocturia revealed participants’ understandings of nocturia, the impact it had on their night and increased daily fatigue. Themes on the intervention showed perceived improvements to nocturia, sleep and energy and negative effects including lethargy, a lack of significant change and physical side effects including vivid dreams.
Conclusion: This qualitative exploration revealed an association between nocturia and increased levels of fatigue during the day by those with MS. However, perspectives towards the effectiveness of melatonin as a potential treatment varied as both placebo and melatonin were perceived as having very similar effects.
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 16, 2018 |
Online Publication Date | Oct 18, 2018 |
Publication Date | Oct 18, 2018 |
Deposit Date | Sep 19, 2018 |
Publicly Available Date | Sep 19, 2018 |
Journal | Multiple Sclerosis International |
Print ISSN | 2090-2654 |
Publisher | Hindawi |
Peer Reviewed | Peer Reviewed |
Volume | 2018 |
Pages | 4721505 |
DOI | https://doi.org/10.1155/2018/4721505 |
Keywords | multiple sclerosis, nocturia, sleep, fatigue, quality of life, melatonin |
Public URL | https://uwe-repository.worktribe.com/output/858572 |
Publisher URL | https://doi.org/10.1155/2018/4721505 |
Contract Date | Sep 19, 2018 |
Files
4721505.pdf
(2.1 Mb)
PDF
You might also like
Longitudinal and idiographic methods of developing and evaluating tailored psychological interventions for people with MS: Findings from a pilot study and future directions
(2024)
Presentation / Conference Contribution
Identifying the key determinants of a community pharmacy based bladder and bowel service
(2024)
Journal Article
The role of community pharmacy in the promotion of continence care: A systematic review
(2024)
Journal Article
CONfidence: Developing an app to promote bladder and bowel health
(2024)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search